SOLVONIS
LIVE

Serial Number

79422293

Owner

Graft Polymer (UK) Plc

Attorney

William C. Wright

Filing Date

Dec 6, 2024

Add to watchlist:

No watchlists yet
View on USPTO

SOLVONIS Trademark

Serial Number: 79422293 • Registration: 8140050

SOLVONIS is a trademark filed by Graft Polymer (UK) Plc on December 6, 2024. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently registered and active.

Owner Contact Info

Graft Polymer (UK) Plc

Eccleston Yards,

Entity Type: 84

Solvonis Therapeutics plc

Eccleston Yards,

Entity Type: 84

Trademark Details

Filing Date

December 6, 2024

Registration Date

February 17, 2026

Published for Opposition

December 30, 2025

Goods & Services

Chemicals and chemical substances for use in industry, in science and chemical preparations for use in the manufacture of pharmaceuticals; biological and biochemical substances being organic chemical compounds, synthetic chemical compounds, enzymes, nucleic acids, non-medical chemical reagents, biochemical catalysts and non-medical diagnostic reagents for use in industry and science, peptide substrates for scientific purposes, proteins for use in manufacture, chemical solvents for use in the manufacture of pharmaceuticals, and small molecule chemical compounds and chemical intermediates for use in the manufacture of pharmaceuticals

Scientific laboratory services; clinical research services, namely, conducting clinical trials for others; scientific advisory, scientific analysis, assessment being quality control for others, assistance being technical support for others being testing and evaluation of clinical, laboratory and medical equipment and software to improve performance and efficiency of such equipment and software, and troubleshooting in the nature of diagnosing problems with clinical, laboratory and medical equipment and software, auditing being quality control for others, consultancy, design, development, due diligence being quality control for others, quality evaluation, scientific information, inspection being quality control for others, research and testing services in the fields of chemicals, of chemical substances, of biological substances, of biochemical substances, of science, of clinical research, of artificial intelligence, of machine learning and of biotechnology; scientific analysis, assessment being quality control for others, assistance being technical support for others being testing and evaluation of clinical, laboratory and medical equipment and software to improve performance and efficiency of such equipment and software, and troubleshooting in the nature of diagnosing problems with clinical, laboratory and medical equipment and software, auditing being quality control for others, design, development, due diligence being quality control for others, quality evaluation, inspection being quality control for others, research and testing services in the fields of medicine, of pharmaceuticals, of medical diagnostics, of biomarkers and of bioinformatics; auditing being quality control for others, design, development, due diligence being quality control for others, inspection being quality control for others and research services in the fields of chemicals, chemical substances, biological substances, biochemical substances and pharmaceuticals for therapy, of telehealth, of mental health, of medical counselling, of psychology, of psychotherapy, of health counselling, of behavioural health counselling, of behavioural health, of behaviour and of addiction

Pharmaceuticals and medical preparations being chemical intermediates, being chemical diagnostic preparations for medical purposes and being chemical preparations, small molecule pharmaceutical preparations and organic and synthetic pharmaceutical compounds for the treatment of neurodegenerative diseases, movement disorders, neurodevelopmental disorders, neurological disorders, conditions and diseases and of central nervous system disorders, conditions and diseases; pharmaceuticals and medical preparations being chemical preparations and small molecule pharmaceutical preparations and organic and synthetic pharmaceutical compounds for the treatment of behavioural health disorders, mental health disorders and addiction

Medical services; pharmaceutical compounding services; cognitive, behavioural, central nervous system, neurological, physical, psycho-social and mental health therapy services; cognitive, behavioural, central nervous system, neurological, physical, psycho-social and mental health telehealth services; mental health services; medical counselling services; psychological counselling services; psychotherapy services; health counselling services; behavioural health counselling services; health care services, namely design and provision of behavioural health treatment programmes; health care services, namely addiction counselling and treatment services; medical services, namely administration, advisory, analysis, assessment, assistance, consultancy, evaluation, information and testing services in the fields of cognitive, behavioural, central nervous system, neurological, physical, psycho-social and mental health therapy, of telehealth, of mental health, of medical counselling, of psychology, of psychotherapy, of health counselling, of behavioural health counselling, of behavioural health, of behaviour and of addiction; medical advisory, consultancy and information services in the fields of medicine, of pharmaceuticals, of medical diagnostics, of biomarkers and of bioinformatics

Filing History

FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
May 17, 2026 FICR
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Feb 17, 2026 NRCC
REGISTERED-PRINCIPAL REGISTER
Feb 17, 2026 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Dec 30, 2025 NPUB
PUBLISHED FOR OPPOSITION
Dec 30, 2025 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Dec 24, 2025 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Dec 5, 2025 CNSA
EXAMINER'S AMENDMENT ENTERED
Dec 3, 2025 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Dec 3, 2025 GNEN
EXAMINERS AMENDMENT E-MAILED
Dec 3, 2025 GNEA
EXAMINERS AMENDMENT -WRITTEN
Dec 3, 2025 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Nov 16, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Nov 16, 2025 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Nov 16, 2025 TROA
REFUSAL PROCESSED BY IB
Aug 16, 2025 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Jul 26, 2025 RFCS
REFUSAL PROCESSED BY MPU
Jul 26, 2025 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Jun 3, 2025 RFCR
NON-FINAL ACTION WRITTEN
Jun 2, 2025 CNRT
ASSIGNED TO EXAMINER
May 27, 2025 DOCK
CHANGE OF NAME/ADDRESS REC'D FROM IB
May 16, 2025 ADCH
APPLICATION FILING RECEIPT MAILED
Apr 25, 2025 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Apr 25, 2025 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Apr 24, 2025 REPR